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The prognostic importance of SIR in patients with cancer is widely recognised. More recently it has become clear that the 
systemic inflammatory response is an important etiologic factor in the development of cancer cachexia. Two recent meta-
analysis carried out in 2017 and 2018 were interrogated and the number of patients with specific cancer types were identified. 
The percentage of patients with operable cancer (n > 28,000) who were systemically inflamed varied from 21% to 38%. The 
percentage of patients with inoperable cancer (n > 12,000) who were systemically inflamed varied from 29% to 79%. Overall, 
the percentage of patients (n > 40,000) who were systemically inflamed varied from 28% to 63% according to tumour type. 







Cancer is the second leading cause of death globally being re-sponsible 
for 9.6 million deaths in 2018 (World Health Organization, 2018. In 
westernised countries, it has been estimated that one in three people will 
develop cancer in their lifetime, and one in four will die from it (Bosanquet 
and Sikora, 2004, World Health Organization, 2017). A curative intent will 
always be the aim of any surgical or on-cological treatment however many 
patients will go on to develop dis-seminated disease requiring best supportive 
care (Dolan et al., 2017b, Dolan et al., 2017a). 
 
In 2014 McAllister and Weinberg concluded that tumour related systemic 
inflammation was the “seventh hallmark of cancer” and the “tip of the iceberg” 
in terms of cancer biology and treatment (McAllister and Weinberg, 2014, 
Mantovani et al., 2008, Paulsen et al., 2017). Furthermore, in two recent 
meta-analyses Dolan and co-workers showed that widely used clinical 
markers of the systemic inflammatory response (SIR) (C-reactive Protein 
[CRP], albumin, neutrophils and platelets) had prognostic value in patients 
with operable and in ad-vanced cancer (Dolan et al., 2017a, Dolan et al., 
2017b). Indeed, the activation of the systemic inflammatory response has been 
strongly implicated in the aggressiveness of the disease and development of 
cachexia with associated deleterious outcomes. It has become clear that the 
systemic inflammatory response is an important etiologic factor in the 
development of cancer cachexia (Arends et al., 2017, Cederholm et al., 2017, 






importance to understand the prevalence of the systemic inflammatory 
response in patients with primary operable cancer and advanced op-erable 
cancer in order to develop strategies to mitigate the effects of the systemic 
inflammatory response, especially in tumour types where the prevalence is 
high. 
The prognostic application of markers of the SIR in patients with cancer 
are usually based around composite ratios or scores of different circulating 
white blood cells or acute phase proteins; representing the systemic responses 
of two different organs, lymphoid/myeloid tissue and liver respectively (Dolan 
et al., 2018b). The most widely validated example of a composite ratio would 
be the neutrophil lymphocyte ratio (NLR) based on the ratio of circulating 
neutrophil and lymphocyte counts (Dolan et al., 2017b). While it is clear that 
composite ratios such as the NLR have prognostic value, there is a large 
variation in the specific threshold levels used which makes comparison of 
studies dif-ficult (Dolan et al., 2017a, Dolan et al., 2017b, Guthrie et al., 
2013a, Watt et al., 2015). The most widely validated example of a cumulative 
scores is the Glasgow Prognostic Score (GPS) and the modified Glasgow 
Prognostic Score (mGPS) based on the acute phase proteins C-reactive 
protein and albumin. The advantage of cumulative scores is that they are 
based on validated laboratory reference ranges and the advantage of the 
GPS/mGPS is that consistent thresholds that allow for direct comparison of 
the SIR across different institutions and geographical locations (Dolan et al., 
2017b, Dolan et al., 2017a). 
 
While the prognostic importance of the SIR in patients with both operable 
and inoperable cancers is widely recognised, the level of 
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systemic inflammation in patients with cancer across the literature has not 
been formally assessed. Therefore, the aim of the present study was to 
determine the prevalence of systemic inflammation as measured by the GPS/ 




The present review of published literature was based on that of two 
previous systematic reviews (Dolan et al., 2017b, Dolan et al., 2017a) 
undertaken according to a pre-defined protocol described in the PRISMA-P 
statement. These reviews recently reported on both operable cancer and 
advanced inoperable cancer. Briefly, these systematic re-views (Dolan et al., 
2017b, Dolan et al., 2017a) carried out a wide-ranging literature search to 
identify studies conducted from January 1947 to 31 st January 2018. Medical 
subject heading (MeSH) terms (Cancer, GPS, Glasgow Prognostic Score, 
mGPS and modified Glasgow Prognostic Score), were used in the US 
National Library of Medicine (MEDLINE), the Excerpta Medica database 
(EMBASE) and the Cochrane Database of Systematic Reviews (CDSR) to 
identify published papers and abstracts. 
 
Animal studies, those not in cancer patients, and trials not available in 
English were excluded. Where there were multiple publications from the 
same cohort the most recent paper was included. Once further ex-clusions 
outlined below were carried out, the bibliographies of all in-cluded articles 
were subsequently hand searched to identify any addi-tional studies. Only 
studies that had greater than 100 observations and reported survival were 




Studies were reviewed and the number of patients with breast, bladder, 
gynaecological, prostate, gastrointestinal, haematological, renal, colorectal, 
head and neck, hepato, pancreato, biliary, pulmonary and multiple types of 
cancer types were grouped into tables for oper-able, inoperable and combined 
studies. The individual number of pa-tients with elevated CRP and albumin 
readings were also included. No meta analysis was carried out since it could 
be considered as a narrative review of previous systematic reviews(Dolan et 





4.1. Study selection process 
 
The review of existing systematic reviews(Dolan et al., 2017b, Dolan et 
al., 2017a) led to a review of the full text of 104 articles. A further 36 articles 
were identified from bibliographies and were in-cluded in this narrative 
review leading to a final total of 140 articles. The details of the 140 studies 
included in the review are shown in Table 1. 
 
 
4.2. Studies of the GPS/ mGPS in patients with breast cancer 
 
No articles were identified in patients with operable breast cancer (Table 
1). Two studies including 181 patients were identified in in-operable breast 
cancer. These studies included both retrospective (n =  
1) and prospective studies (n = 1). These included studies carried out in the 
UK (n = 1) and Germany (n = 1). In total 81 (45%) of patients were 
systematically inflamed (Tables 1 and 2). 
 
4.3. Studies of the GPS/ mGPS in patients with bladder cancer 
 
Two studies including 2133 patients were identified in operable bladder 
cancer. These studies were both retrospective studies (n = 2). These included 
studies carried out in Italy (n = 1) and Japan (n = 1). In total 723 (34%) of 
patients were systematically inflamed (Tables 1 
 
 
and 2). A single study was identified in patients with inoperable bladder 
cancer. This contained 67 patients, was prospective, carried out in Korea and 
showed that 34 (51%) of patients were systemically in-flamed. 
 
4.4. Studies of the GPS/ mGPS in patients with gynaecological cancer 
 
Three studies including 724 patients were identified in operable 
gynaecological cancer. These studies included both retrospective (n =  
2) and prospective studies (n = 1). These included studies carried out in 
Austria (n = 1), Japan (n = 1) and China (n = 1). In total 186 (26%) of patients 
were systematically inflamed (Tables 1 and 2).  
Three studies including 870 patients were identified in inoperable 
gynaecological cancer. These studies included both retrospective (n = 
2) and prospective studies (n = 1). These included studies carried out in 
multiple countries (n = 1), Austria (n = 1) and China (n = 1). In total 309 
(36%) of patients were systematically inflamed (Tables 1 and 
2).  
 
4.5. Studies of the GPS/ mGPS in patients with prostate cancer 
 
No articles were identified in patients with operable prostate cancer 
(Tables 1 and 2). Two studies including 223 patients were identified in 
inoperable prostate cancer. These studies included both retrospective (n  
= 1) and prospective studies (n = 1). These included studies carried out in 
multiple countries (n = 1) and Japan (n = 1). In total 65 (29%) of patients 
were systematically inflamed (Tables 1 and 2). 
 
4.6. Studies of the GPS/ mGPS in patients with gastro-oesophageal cancer 
 
Twenty-five studies including 7,693 patients were identified in op-erable 
gastro-oesophageal cancer. These studies included both retro-spective (n = 
24) and prospective studies (n = 1). These included studies carried out in 
Japan (n = 13), UK (n = 5), China (n = 3), Germany (n = 2), Ireland (n = 1) 
and Italy (n = 1). In total 1,617 (21%) of patients were systematically 
inflamed (Tables 1 and 2).  
Eleven studies including 1,897 patients were identified in inoper-able 
gastro-oesophageal cancer. These studies included both retro-spective (n = 
10) and prospective studies (n = 1). These included studies carried out in the 
UK (n = 3), Japan (n = 3), Korea (n = 2), China (n = 1), Czech Rep (n = 1) 
and Taiwan (n = 1). In total 1032 (54%) of patients were systematically 
inflamed (Tables 1 and 3). 
 
4.7. Studies of the GPS/ mGPS in patients with haematological cancer 
 
Two studies including 430 patients were identified in inoperable 
haematological cancer. All studies were retrospective. These included studies 
carried out in China (n = 1) and Korea (n = 1). In total 340 (79%) of patients 
were systematically inflamed (Tables 1 and 3). 
 
4.8. Studies of the GPS/ mGPS in patients with renal cancer 
 
Seven studies including 2417 patients were identified in operable renal 
cancer. These studies included both retrospective (n = 6) and prospective 
studies (n = 1). These included studies carried out in the UK (n = 2), Japan (n 
= 4) and Korea (n = 1). In total 717 (30%) of patients were systematically 
inflamed (Tables 1 and 2).  
Two studies including 142 patients were identified in inoperable renal 
cancer. These studies included both retrospective (n = 1) and prospective 
studies (n = 1). These studies were both carried out in the UK. In total 101 
(45%) of patients were systematically inflamed (Tables 1 and 3). 
 
 
4.9. Studies of the GPS/ mGPS in patients with colorectal cancer 
 































Table 1  
Studies using mGPS to stratify patients undergoing operative and non-operative treatment for cancer.  
 
No: GPS/mGPS Study Type of Study Cancer Country Patients (n) Measure of SIR CRP > 10 Albumin GPS/mGPS GPS/mGPS GPS/mGPS Additional Treatment 
       mg/l < 35 g/l 0 1  2  
              
Breast cancer Operable              
1.     _    _ _  _  
Breast cancer Inoperable              
1. Al Murri Retrospective Breast cancer UK 96 GPS (0/1/2) 45 (47) 6 (6) 51 (53) 39 (41) 6 (6) Chemotherapy and 
 et al., 2006            endocrine therapy 
2. Honecker Prospective Breast cancer Germany 85 GPS (0/1/2) 36 17 49 (57.6) 22 (25.9) 14 (16.5) First line chemotherapy 
 et al., 2018             
Combined Total     181    100 (55.2) 61 (33.7) 20 (11.1)  
Bladder cancer Operable              
1 Ferro et al., Retrospective Bladder cancer Italy 1037 mGPS (0/1/2) 391 (37.7) 97 (9.4) 646 (62.3) 297 (28.6) 94 (9.1) 77.1% received adjuvant 
 2015            chemotherapy 
2 Kimura et al., Retrospective Bladder cancer Japan 1096 mGPS _ _ 764 (69.7) 299 (27.3) 33 (3.0) 4.0% patients received 
 2019            adjuvant chemotherapy 
Bladder cancer              
Inoperable              
1. Hwang et al., Prospective Bladder cancer Korea 67 GPS (1&2) 30 (44.8) 21 (31.3) 33 (49.3) 17 (25.4) 17 (25.4) Treated with 
 2012            chemotherapy 
Combined Total     2200    1443 (65.6) 613 (27.9) 144 (6.5)  
Gynaecological cancer              
Operable              
1. Hefler- Prospective Vulval cancer Austria 93 GPS (0/1/2) _ _ 72 (77.4) 16 (17.2) 5 (5.4) Adjuvant treatment not 
 Frischmuth            specified 
 et al., 2010             
2. Saijo et al., Retrospective Endometrial cancer Japan 431  51 (11.8) 21 (4.9) 376 (87.2) 38 (8.8) 17 (4.0) Adjuvant chemotherapy 
 2017            in high risk patients 
3. Liu et al., Retrospective Ovarian cancer China 200 mGPS (0/1/2) 41 (20.5) 6 (3.0) 90 (45) 90 (45) 20 (10) 96% patients received 
 2017            chemotherapy 
Gynaecological cancer              
Inoperable              
1. Xiao et al., Retrospective Cervical cancer China 238 mGPS (0/1/2) 107 (45.0) 29 (12.2) 138 (58.0) 71 (29.8) 29 (12.2) Chemotherapy and 
 2015            radiotherapy 
2. Roncolato Prospective Endometrial cancer Multinational 516 mGPS (0/1/2) _ _ 282 (54.7) 123 (23.8) 111 (21.5) Chemotherapy and best 
 et al., 2018            supportive care 
3. Seebacher Retrospective Cervical cancer Austria 116 GPS _ _ 41 (35.3) 56 (48.3) 19 (16.4) Best supportive care for 
 et al., 2019            recurrent disease 
Combined Total     1594    999 (62.7) 394 (24.7) 201 (12.6)  
Prostate cancer              
Operable              
1.     _    _ _  _  
Total              
Prostate cancer              
Inoperable              
1. Linton et al., Prospective Prostate cancer Multinational 112 mGPS (2 vs. 0) >5: 36 27 (24.1) 76 (67.9) 17 (15.2) 19 (16.9) Docetaxel and prednisone 
 2013     (1 vs. 0) (32.1)      treatment 
2. Owari et al., Retrospective Renal, prostate and Japan 111 mGPS (0/1/2) _ _ 82 (74) 26 (23) 3 (3) 84% treated with 
 2018  urethral cancer          radiotherapy 








































































Table 1 (continued)  
 
No: GPS/mGPS Study Type of Study Cancer Country Patients (n) Measure of SIR CRP > 10 Albumin GPS/mGPS GPS/mGPS GPS/mGPS Additional Treatment 
       mg/l < 35 g/l 0 1 2  
             
1. Kobayashi Retrospective Oesophageal Japan 48 GPS (0/ 1 and _ _ 27 (56.3) 16 (33.3) 5 (10.4) Neoadjuvant 
 et al., 2008  squamous cell   2)      chemoradiotherapy 
   carcinoma         (nCRT) 
2. Kobayashi Retrospective Oesophageal Japan 65 GPS (0 and 1) _ _ 43 (66.2) 16 (24.6) 6 (9.2) 60% patients received 
 et al., 2010b  squamous cell         neoadjuvant 
   carcinoma         chemoradiotherapy 
3. Dutta et al., Retrospective Oesophageal cancer UK 112 GPS (0/1/2) _ _ 99 (88.4) 13 (11.6) 0 (0) 27.7% patients received 
 2011b           neoadjuvant therapy and 
            12.5% received adjuvant 
            therapy 
4. Dutta et al., Retrospective Gastro-oesophageal UK 121 GPS (0/1/2) _ _ 99 (81.8) 16 (13.2) 6 (5.0) 55.4% patients received 
 2011a  cancer         neoadjuvant and 15.7% 
            received adjuvant 
            therapy 
5. Crumley Retrospective Gastro-oesophageal UK 100 GPS (0/1/2) _ _ 87 (87) 13 (13) 0 (0) Adjuvant and 
 et al., 2011  cancer         neoadjuvant therapy 
6. Vashist et al., Retrospective Oesophageal cancer Germany 495 GPS (0/1/2) _ _ 268 (54.1) 166 (33.5) 61 (12.3) No adjuvant or 
 2011           neoadjuvant therapy 
7. Dutta et al., Retrospective Oesophageal cancer UK 98 GPS (0/1/2) _ _ 87 (88.8) 9 (9.2) 2 (2.0) 48.0% received 
 2012b           neoadjuvant therapy and 
            18.4% received adjuvant 
            therapy 
8. Feng et al., Retrospective Oesophageal cancer China 493 GPS (0/1/2) _ _ 316 (64.1) 121 (24.5) 56 (11.4) Adjuvant chemotherapy 
 2014           and radiotherapy 
9. Nakamura Retrospective Oesophageal cancer Japan 168 mGPS (0/1/2) _ _ 137 (81.6) 19 (11.3) 12 (7.1) 7.7% received 
 et al., 2014           neoadjuvant therapy 
            while 36.9% received 
            adjuvant therapy 
10. Matsuda Retrospective Oesophageal cancer Japan 199 GPS (0/1/2) 10 (5.0) 12 (6.0) 108 (54.3) 68 (34.2) 23 (11.5) 49.8% patients received 
 et al., 2015           neoadjuvant 
            chemotherapy and 
            radiotherapy 
11. Arigami et al., Retrospective Oesophageal cancer Japan 238 mGPS (0/1/2) _ _ 168 (70.6) 54 (22.7) 16 (6.7) Adjuvant therapy not 
 2015           specified 
12. Xu et al., 2015 Retrospective Oesophageal China 468 GPS/mGPS (0/ 108 (23) 89 (19) GPS: 336 GPS: 101 GPS: 31 41.9% patient received 
   squamous cell   1/2)   (71.8) (21.6) (6.6) adjuvant chemotherapy 
   carcinoma      mGPS: 360 mGPS: 77 mGPS: 31 and radiotherapy 
         (76.9) (16.5) (6.6)  
13. Hirahara Retrospective Oesophageal cancer Japan 141 GPS (0/1/2) 18 (12.8) 27 (19.1) 109 (77.3) 23 (16.3) 9 (6.4) Adjuvant therapy not 
 et al., 2015           specified 
14. Walsh et al., Retrospective Oesophageal cancer Ireland 223 mGPS (0 vs. 1/ _ _ 174 (78.0) _ mGPS 1&2: 48.9% patients received 
 2016     2)     49 (22.0) neoadjuvant 
            chemoradiotherapy, 
            29.6% patients received 
            chemotherapy 
15. Otowa et al., Retrospective Oesophageal cancer Japan 100 Pre-NAC mGPS _ _ Pre: 82 Pre: 7 (7.0) Pre: 11 All patients received 
 2016     (0/1-2)   (82.0)  (11.0) neoadjuvant 
      Post-NAC   Post: 90 Post: 0 (0) Post: 10 chemotherapy 
      mGPS (0/2)   (90.0)  (10.0)  













































Table 1 (continued)  
 
 No: GPS/mGPS Study Type of Study Cancer Country Patients (n) Measure of SIR CRP > 10 Albumin GPS/mGPS GPS/mGPS GPS/mGPS Additional Treatment 
        mg/l < 35 g/l 0 1 2   
              
16. Toyokawa Retrospective Thoracic Oesophageal Japan 185 GPS (0 vs 1/2) _ _ 171 (92.5) 13 (7.0) 1 (0.5) 24.9% patients received 
  et al., 2016  Squamous Cell          neoadjuvant therapy 
    Carcinoma           
17. Nozoe et al., Prospective Gastric cancer Japan 232 GPS (0/1/2) 58 (25.0) 62 (26.7) 140 (60.3) 64 (27.6) 28 (12.1) Adjuvant therapy not 
  2011     mGPS (0/1/2)       specified 
18. Kubota et al., Retrospective Gastric cancer Japan 1017 GPS (0/1/2) _ _ 956 (94.0) 40 (3.9) 21 (2.1) Adjuvant therapy not 
  2012            specified 
19. Dutta et al., Retrospective Gastric cancer UK 120 GPS (0/1/2) _ _ 97 (80.8) 18 (15.0) 5 (4.2) Patients received both 
  2012a            adjuvant and 
              neoadjuvant therapy 
20. Wang et al., Retrospective Gastric cancer China 324 GPS (0/1/2) 62 (19.1) 32 (9.9) 248 (76.5) 58 (17.9) 18 (5.6) 64.8% patients received 
  2012            adjuvant chemotherapy 
21. Jiang et al., Retrospective Gastric cancer Japan 1710 mGPS (0/1/2) 145 (8.5) 162 (9.5) 1565 (91.5) 78 (4.6) 67 (3.9) Adjuvant therapy not 
  2012            specified 
22. Takeno et al., Retrospective Gastric cancer Japan 552 mGPS (0/1/2) _ _ 494 (89.5) 24 (4.3) 34 (6.2) Adjuvant therapy not 
  2014            specified 
23. Hirashima Retrospective Gastric cancer Japan 294 mGPS (0/1/2) _ _ 174 (59.2) 84 (28.6) 36 (12.2) 3.1% patients received 
  et al., 2014            neoadjuvant 
              chemotherapy 
24. Aurello et al., Retrospective Gastric cancer Italy 102 mGPS (0/1/2) 53 (51.9) 55 (53.9) 49 (48.0) 25 (24.5) 28 (27.5) 66.7% patients received 
  2014            adjuvant chemotherapy 
25. Melling et al., Retrospective Gastric cancer Germany 88 GPS (0/1/2) _ _ 42 (47.7) 22 (25.0) 24 (27.3) Neoadjuvant and 
  2016            adjuvant therapy not 
              specified 5 
Gastro-oesophageal 
             
              
 cancer Inoperable              
1. Crumley Retrospective Gastro-oesophageal UK 258 GPS (0/1/2) _ _ 92 (36) 121 (47) 45 (17) Palliative chemotherapy 
  et al., 2006  cancer          and radiotherapy 
2. Crumley Retrospective Gastro-oesophageal UK 65 GPS (0/1/2) _ _ 26 (40) 31 (48) 8 (12) Cisplatin based 
  et al., 2008  cancer          chemotherapy 
3. Zhang et al., Retrospective Oesophageal cancer China 212 mGPS (0,1,2) 122 (57.6) 134 (63.3) 90 (42.5) 78 (36.8) 44 (20.8) Radiotherapy and 
  2014            cisplatin based chemo 
4. Elahi et al., Retrospective Gastric and colorectal UK Gastric: 66 GPS (0/1/2) 47 (71.2) 25 (37.9) Gastric: 17 Gastric: 26 Gastric: 23 Palliative chemotherapy 
  2004  cancer      (25.8) (39.4) (34.8) and supportive care 
5. Hwang et al., Retrospective Gastric cancer Korea 402 GPS: (1&2) 140 (34.9) 77 (19.2) 238 (59.2) 111 (27.6) 53 (13.2) Cisplatin based 
  2011            chemotherapy 
6. Jeong et al., Retrospective Gastric cancer Korea 104 mGPS: (1 & 2) _ _ 58 (55.8) 29 (27.9) 17 (16.3) Palliative chemotherapy 
  2012             
7. Sachlova Retrospective Gastric cancer Czech Rep 91 Total 64 GPS (1&2) _ _ 37 (41) 31 (34) 23 (25) Palliative platinum based 
  et al., 2014    (treated with        chemotherapy 
      chemo)         
8. Namikawa Retrospective Gastric cancer Japan 244 GPS (0/1 or 2) _ _ GPS:150 GPS: _ GPS: 1&2: Combination 
  et al., 2016        (61.5)  94 (38.5) chemotherapy including 
       mGPS (0/1 or _ _ mGPS: 143 mGPS: _ mGPS 1&2: trastuzmab 
       2)   (58.6)  101 (41.4)  
9. Arigami et al., Retrospective Gastric cancer Japan 68 GPS: 1&2 _ _ 35 (51.5) 27 (39.7) 6 (8.8) Chemotherapy and 
  2016            chemoradiotherapy 
10. Hsieh et al., Retrospective Gastric cancer Taiwan 256 mGPS (> 1) _ _ 66 (26) 100 (39) 90 (35) Combination 
  2016            Chemotherapy 
11. Okuno et al., Prospective Oesophageal cancer Japan 131 GPS (0/1/2) _ _ 56 (42.8) 48 (36.6) 27 (20.6) Radiotherapy and 
  2017            standard cisplatin vs. 
              Radiotherapy and low 
              dose cisplatin  




































































Table 1 (continued)  
 
No: GPS/mGPS Study Type of Study Cancer Country Patients (n) Measure of SIR CRP > 10 Albumin GPS/mGPS GPS/mGPS GPS/mGPS Additional Treatment 
       mg/l < 35 g/l 0 1 2   
             
Combined Total     9590    6941 (72.4) 1670 (17.4) 979 (10.2)  
Haematological cancer              
Inoperable              
1. Chou et al., Retrospective Haematological China 217 GPS: (1&2) 181 (83.4) 156 (71.9) 15 (6.9) 56 (30.9) 146 (62.2) Best supportive palliative 
 2015  cancer          care 
2. Jung et al., Retrospective B-cell Lymphoma Korea 213 L-GPS: 1&2 135 (63.4) 43 (20.2) 75 (35.2) 109 (51.2) 29 (13.6) R-CHOP chemotherapy. 
 2015             
Combined Total     430    90 (20.9) 165 (38.4) 175 (40.7)  
Renal cancer Operable              
1. Qayyum Prospective Renal cell cancer UK 79 GPS (0/1/2) _ _ 57 (72.2) 19 (24.1) 3 (3.7) Adjuvant therapies not 
 et al., 2012            specified 
2. Lamb et al., Retrospective Renal cancer UK 169 GPS (0/1/2) _ _ 117 (69.2) 46 (27.2) 6 (3.6) Adjuvant therapies not 
 2012            specified 
3. Tsujino et al., Retrospective Renal cancer Japan 219 mGPS (0/1/2) _ _ 184 (84.0) 20 (9.1) 15 (6.9) Adjuvant therapies not 
 2017            specified 
4. Fukuda et al., Retrospective Renal cancer Japan 170 GPS (0/1/2) _ _ 56 (33) 67 (39) 47 (28) Chemotherapy and 
 2018            immunotherapy as part of 
             cryoreductive treatment 
5. Inamoto et al., Retrospective Urethreal cancer Japan 574 GPS (0/1/2) _ _ 332 (57.8) 132 (23.0) 110 (19.2) Adjuvant therapies not 
 2017            specified 
6. Son et al., Retrospective Urethelial cancer South Korea 1137 mGPS (0/1/2) 219 (19.3) 158 (13.8) 918 (80.7) 148 (13.0) 71 (6.2) 30.6% treated with 
 2018            adjuvant chemotherapy 
7. Owari et al., Retrospective Renal and urethral Japan 69 GPS (0/1/2) _ _ 36 (52.2) 19 (27.5) 14 (20.3) 56.5% treated with 
 2018  cancer          radiotherapy 
Renal cancer Inoperable              
1. Ramsey et al., Retrospective Renal cell cancer UK 119 GPS: (0/1/2) 84 (71) 16 (14) 33 (28) 72 (60) 14 (12) Active Immunotherapy 
 2007             
2. Ramsey et al., Prospective Renal cell cancer UK 23 GPS (0/1/2) _ _ 8 (35) 6 (26) 9 (39) Palliative 
 2008            immunotherapy 
Combined Total     2559    1741 (68.0) 529 (20.7) 289 (11.3)  
Colorectal Cancer              
Operable              
1. Ishizuka et al., Retrospective Colorectal cancer Japan 315 GPS (0/1/2) 76 (24.1) 100 (21.8) 183 (58.1) 89 (28.3) 43 (13.6) Neoadjuvant treatments 
 2007            not specified 
2. McMillan Retrospective Colorectal cancer UK 316 mGPS (0/1/2) 101 (32.0) 54 (17.1) 185 (58.5) 93 (29.5) 38 (12.0) Adjuvant therapy not 
 et al., 2007            specified 
3. Leitch et al., Retrospective Colorectal cancer UK 149 mGPS (0/1/2) 61 (40.9) 14 (9.4) 88 (59.1) 48 (32.2) 13 (8.7) 47.7% of patients 
 2007a            received adjuvant 
             therapy 
4. Roxburgh Retrospective Colorectal cancer UK 287 mGPS (0/1/2) _ _ 171 (60) 82 (28) 34 (12) Adjuvant therapy not 
 et al., 2009            specified 
5. Ishizuka et al., Retrospective Colorectal liver Japan 93 GPS (0/1/2) _ _ 63 (67.7) 24 (25.8) 6 (6.5) Neoadjuvant therapy not 
 2009a  metastases          specified 
6. Crozier et al., Prospective Colon cancer UK 188 mGPS (0/1/2) _ _ 79 (42.0) 80 (42.6) 29 (15.4) 28.7% patients received 
 2009            adjuvant therapy 
7. Roxburgh Retrospective Colon cancer UK 287 mGPS (0/1/2) _ _ 143 (57) 102 (33) 42 (10) Adjuvant chemotherapy 
 et al., 2010             
8. Richards Prospective Colorectal cancer UK 320 mGPS (0/1/2) _ _ 194 (61) 90 (28) 36 (11) 20.6% had adjuvant 
 et al., 2010            therapy 
9. Kobayashi Retrospective Colorectal liver Japan 63 GPS (0/ 1 and _ _ 57 (90.5) 4 (6.3) 2 (3.2) 84.1% patients received 
 et al., 2010a  metastases   2)       adjuvant chemotherapy  




































































Table 1 (continued)  
 
No: GPS/mGPS Study Type of Study Cancer Country Patients (n) Measure of SIR CRP > 10 Albumin GPS/mGPS GPS/mGPS GPS/mGPS Additional Treatment 
       mg/l < 35 g/l 0  1  2   
                
10. Moug et al., Retrospective Colorectal cancer UK 206 GPS (0/1/2) _ _ 113 (54.9) 53 (25.7) 40 (19.4) 4.4% received 
 2011              neoadjuvant and 23.3% 
               received adjuvant 
               therapy 
11. Roxburgh Retrospective Colorectal cancer UK 302 GPS (0/1/2) 115 (38.1) 39 (12.9) 188 (62) 85 (28) 29 (10) 23.5% patients received 
 et al., 2011b              adjuvant therapy 
12. Roxburgh Retrospective Colon cancer UK 76 mGPS (0/1 or 42 (55.3) 31 (40.8) 34 (44.7) 33 (43.5) 9 (11.8) 100% patients received 
 et al., 2011a     2)         adjuvant chemotherapy 
13. Richards Retrospective Colorectal cancer UK 343 GPS (0/1/2) _ _ 194 (56.6) 112 (32.7) 37 (10.7) Adjuvant therapies not 
 et al., 2012              specified 
14. Sugimoto Retrospective Colorectal cancer Japan 366 GPS (0/1/2) _ _ mGPS 0/1: _  31 (8.5) Adjuvant chemotherapy 
 et al., 2012        335 (91.5)      
15. Powell et al., Prospective Colorectal cancer UK 411 mGPS (0/1/2) 181 (44.0) 74 (18.0) 243 (59.1) 125 (30.4) 43 (10.5) Adjuvant therapies not 
 2012              specified 
16. Ishizuka et al., Retrospective Colorectal cancer Japan 271 GPS (0/1/2) _ _ 176 (64.9) _  mGPS 1&2: 28.1% patients received 
 2012b            95 (35.1) adjuvant chemotherapy 
17. Guthrie et al., Retrospective Colorectal cancer UK 206 mGPS (0/1/2) _ _ 132 (64) 33 (16) 41 (20) 28.2% patients received 
 2013a,b              adjuvant chemotherapy 
18. Ishizuka et al., Retrospective Colorectal Stage IV Japan 108 GPS 2 vs. 0,1 45 (41.7) 55 (50.9) 37 (34.2) 42 (38.9) 29 (26.9) Adjuvant chemotherapy 
 2013b  cancer             
19. Ishizuka et al., Retrospective Colorectal cancer Japan 480 GPS (0/1/2) _ _ 270 (56.3) 150 (31.2) 60 (12.5) Patients with stage IV 
 2013a              received chemotherapy 
20. Son et al., Retrospective Colon cancer Korea 546 mGPS (2 vs. 0- _ _ 433 (80.0) 93 (17.0) 20 (3.0) 92.1% patients received 
 2013     1)         chemotherapy 
21. Nozoe et al., Retrospective Colorectal cancer Japan 272 GPS (0/1/2) _ _ 179 (65.8) 62 (22.8) 31 (11.4) Adjuvant therapies not 
 2014              specified 
22. Forrest et al., Retrospective Colorectal cancer UK 134 mGPS (0/1/2) 54 (40) _ 80 (60) 32 (24) 22 (16) Adjuvant therapies not 
 2014              specified 
23. Sun et al., Retrospective Colon cancer China 255 mGPS (0/1/2) _ _ 163 (63.9) 71 (27.8) 21 (8.3) Neoadjuvant or adjuvant 
 2014              not specified 
24. Nakagawa Retrospective Colorectal liver Japan 343 mGPS (0/1/2) _ _ 295 (86.0) 33 (9.6) 15 (4.4) 20.1% patients received 
 et al., 2014  metastases            neoadjuvant 
               chemotherapy and 63.0% 
               received adjuvant 
               chemotherapy 
25. Shibutani Retrospective Colorectal cancer Japan 254 GPS (0/1/2) _ _ 174 (68.5) 44 (17.3) 36 (14.2) Adjuvant chemotherapy 
 et al., 2015               
26. Ishizuka et al., Retrospective Colorectal cancer Japan 627 GPS (2/0, 1) _ _ 346 (55.3) 177 (28.2) 104 (16.5) Adjuvant therapies not 
 2016              specified 
27. Park et al., Retrospective Colorectal cancer UK 228 GPS (0/1/2) _ _ 131 (58) 71 (31) 26 (11) 57.5% received adjuvant 
 2016a              therapy 
28. Park et al., Retrospective Colorectal cancer UK 1000 mGPS (0/1/2) 370 (37.0) 260 (26.0) 635 (63.5) 207 (20.7) 158 (15.8) 24.8% received adjuvant 
 2016b              therapy and 9.8% 
               received neoadjuvant 
               therapy 
29. Chan et al., Retrospective Colorectal cancer Australia 386 mGPS (0/1/2) _ _ 155 (40.2) 53 (13.7) 178 (46.1) Patients with high-risk 
 2016              stage II and III colon 
               cancer received adjuvant  
chemotherapy and those  
with stage II or III rectal  
cancers received  
neoadjuvant therapy 
 




































































Table 1 (continued)  
 
No: GPS/mGPS Study Type of Study Cancer Country Patients (n) Measure of SIR CRP > 10 Albumin GPS/mGPS GPS/mGPS GPS/mGPS Additional Treatment 
       mg/l < 35 g/l 0  1  2   
                
Colorectal Cancer                
Inoperable                
1. Elahi et al., Retrospective Gastric and colorectal UK 99 GPS (0/1/2) 71 (71.7) 26 (26.3) 28 (28.3) 45 (45.5) 26 (26.2) Palliative chemotherapy 
 2004  cancer            and best supportive care 
2. Read et al., Prospective Colorectal cancer Australia 48 GPS (0/1/2) 48 (69) 14 (7) 15 (31) 26 (54) 7 (15) Palliative chemotherapy 
 2006              and radiotherapy as well 
               as supportive care 
3. Leitch et al., Retrospective Colorectal liver UK 84 GPS (0,1,2) _ _ 17 (20) 44 (52) 23 (28) Palliative chemotherapy 
 2007b  metastases             
4. Ishizuka et al., Retrospective Colorectal cancer Japan 112 mGPS: 1/2 40 (36) 79 (71) 72 (64) 4 (4) 36 (32) FOLFIRI and FOLFOX 
 2009b              chemotherapy 
5. Inoue et al., Retrospective Colorectal cancer Japan 245 mGPS (1-2 vs. _ _ 133 (54.3) 78 (31.8) 34 (13.9) FOLFOX and FOLFIRI 
 2013     0)         chemotherapy 
6. Dreanic et al., Retrospective Colorectal cancer France 27 mGPS: 2 _ _ _  _  27 (100) 5-fluorouracil-based 
 2015     Inverse mGPS:         systemic chemotherapy 
      2         and anti-VEGF 
7. Song et al., Retrospective Colorectal cancer Korea 177 mGPS: (0 vs. 1 63 (35.6) 13 (7.3) 114 (64.4) 52 (29.4) 11 (6.2) Best supportive care 
 2015     or 2)          
8. Thomsen Prospective Colorectal cancer Norway and 374 mGPS (0/1/2) _ _ 165 (44.1) 166 (44.4) 43 (11.5) Cetuximab and FLOX vs. 
 et al., 2016   Denmark           Cetuximab and 
               intermittent FLOX 
Combined Total     9998    6020 (60.2) 2503 (25.0) 1475 (14.8)  
Head and Neck Operable                
1. Farhan-Alanie Retrospective Oral SCC UK 178 GPS (0/1/2) _ _ 131 (74) 25 (14) 22 (12) 70 patients had adjuvant 
 et al., 2015              therapy 
Head                
andNeckInoperable                
1. Li et al., 2017 Prospective Nasopharyngeal China 249 GPS (0/1/2) - - 209 (83.9) 33 (13.3) 7 (2.8) 5.2% received 
   cancer            radiotherapy and 94.8% 
               received 
               chemoradiotherapy 
2. Chang et al., Retrospective Head and neck cancer Taiwan 143 GPS (0/1/2) - - 39 (27.3) 72 (50.3) 32 (22.4) Concurrent 
 2017b              chemoradiotherapy 
3. Chang et al., Retrospective Head and neck cancer Taiwan 139 GPS (0/1/2) - - 32 (23.0) 72 (51.8) 35 (25.2) All patients treated with 
 2017a              concurrent 
               chemoradiotherapy 
Combined Total     709    411 (58.0) 202 (28.5) 96 (13.5)  
Hepato Pancreato                
Biliary Cancer                
Operable                
1. Jamieson Prospective Pancreatic ductal UK 135 GPS (0/1/2) _ _ 74 (54.8) 31 (23.0) 30 (22.2) 54.8% patients received 
 et al., 2011  cancer            adjuvant therapy 
2. La Torre et al., Retrospective Pancreatic cancer Italy 101 GPS (0/1/2) _ _ 32 (31.7) 35 (34.7) 34 (33.6) 25.7% of patients 
 2012              received adjuvant 
               chemotherapy and 
               radiotherapy 
3. Jamieson Retrospective Pancreatic ductal UK 173 mGPS (0/1/2) _ _ 95 (26.3) 37 (13.7) 41 (10.3) 38.7% patients received 
 et al., 2012  adenocarcinoma            adjuvant chemotherapy 
4. Stotz et al., Retrospective Pancreatic cancer Austria 110 GPS (0/1/2) _ _ 73 (66.7) 21 (19) 16 (14.3) 80.0% received 
 2013              chemotherapy 
5. Wu et al., Retrospective Gallbladder cancer China 85 GPS (0 vs 1/2) > 10: 43 < 35: 14 38 (44.7)   GPS 1&2: 47 15.3% patients received 
 2014      (50.6) (16.5)     (55.3) adjuvant chemotherapy  




































































Table 1 (continued)  
 
No: GPS/mGPS Study Type of Study Cancer Country Patients (n) Measure of SIR CRP > 10 Albumin GPS/mGPS GPS/mGPS GPS/mGPS Additional Treatment 
       mg/l < 35 g/l 0 1 2  
             
6. Shiba et al., Retrospective Gallbladder cancer Japan 51 GPS (0/1/2) _ _ 38 (74.5) 8 (15.7) 5 (9.8) Neoadjuvant and 
 2015           adjuvant therapy not 
            specified 
7. Oshiro et al., Retrospective Cholangiocarcinoma Japan 62 GPS (0/1/2) _ _ 32 (50) 20 (34) 10 (16) Neoadjuvant and 
 2013           adjuvant therapy not 
            specified 
8. Shiba et al., Retrospective Carcinoma of the Japan 30 GPS (0/1/2) _ _ 23 (76.7) 5 (16.7) 2 (6.6) Neoadjuvant and 
 2013  ampulla of vater         adjuvant therapy not 
            specified 
9. Ishizuka et al., Retrospective HCC Japan 300 hGPS (0, 1/2) >3: 63 150 (50.0) 237 (79.0) 22 (7.3) 41 (13.7) Neoadjuvant and 
 2011     *CRP > 0.3 (21.0)     adjuvant therapy not 
      mg/dl      specified 
10. Ishizuka et al., Retrospective HCC Japan 398 GPS (0, 1/2) 263 (66.1) 238 (59.8) 156 (39.2) 214 (53.8) 28 (7.0) Neoadjuvant and 
 2012a           adjuvant therapy not 
            specified 
11. Horino et al., Retrospective HCC Japan 352 GPS (0/1/2) 26 (7.4) 61 (17.3) 280 (79.5) 57 (16.2) 15 (4.3) Neoadjuvant and 
 2013           adjuvant therapy not 
            specified 
12. Huang et al., Prospective HCC China 349 GPS (0/1/2) 19 (5.4) 10 (2.9) 278 (79.7) 61 (17.4) 10 (2.9) Neoadjuvant and 
 2014           adjuvant therapy not 
            specified 
13. Ni et al., 2015 Retrospective HCC China 367 GPS (0/1/2) _ _ GPS: 318 GPS: 45 GPS: 4 (1.1) Neoadjuvant and 
         (86.6) (12.3)  adjuvant therapy not 
14. Okamura Retrospective HCC Japan 256 mGPS (0/1/2) _ _ mGPS: 331 mGPS: 32 mGPS: 4 specified 
 et al., 2015        (90.2) (8.7) (1.1)  
      GPS (0/1/2)   226 (88.3) 26 (10.2) 4 (1.5) Neoadjuvant and 
            adjuvant therapy not 
            specified 
15. Abe et al., Retrospective HCC Japan 46 GPS (0/ 1,2) 3 (6.5) 32 (69.6) 14 (30.4) _ mGPS 1&2: Neoadjuvant and 
 2016          32 (69.6) adjuvant therapy not 
            specified 
16. Fu et al., 2016 Retrospective HCC China Training: 772 GPS (0/1/2) _ _ GPS 0: 672 GPS 1: 91 GPS 2: 9 Neoadjuvant and 
         (87.0) (11.8) (1.2) adjuvant therapy not 
      mGPS (0/1/2)   mGPS 0: mGPS 1: 68 mGPS 2: 8 specified 
         696 (90.2) (8.8) (1.0)  
Hepato Pancreato             
Biliary Cancer             
Inoperable             
1. Glen et al., Retrospective Pancreatic cancer UK 187 GPS (0/1/2) 120 (64) 62 (33) 56 (30) 80 (43) 51 (27) Palliative treatment with 
 2006           platinum based 
            chemotherapy 
2. Martin et al., Retrospective Pancreatic cancer Australia 124 mGPS: (0,1,2) _ _ 46 (37) 26 (21) 52 (42) Chemotherapy for 
 2014           metastatic disease and 
            radiotherapy for locally 
            advanced disease 
3. Kasuga et al., Retrospective Pancreatic cancer Japan 61 mGPS: 2 17 (27.9) 22 (36.1) mGPS 0/1: _ mGPS: 2 12 Gemcitabine and S-1 
 2015        49 (80.3)  (19.7) combination therapy 
            (FGS) as salvage 
            chemotherapy 
4. Mitsunaga Prospective Pancreatic cancer Japan 280 mGPS: 1 &2 >5: 46 _ 79 (56.0) 39 (27.7) 23 (16.3) GEM chemotherapy 
 et al., 2016    (Prospective:  (32.6)      
     141)         





































































Table 1 (continued)  
 
No: GPS/mGPS Study Type of Study Cancer Country Patients (n) Measure of SIR CRP > 10 Albumin GPS/mGPS GPS/mGPS GPS/mGPS Additional Treatment 
       mg/l < 35 g/l 0 1 2   
              
 Moriwaki Retrospective Biliary tract cancer Japan Total: 62 Continuous: _ _ 19 (30.6) 17 (27.4) 26 (42.0) Chemotherapy with GEM 
 et al., 2014     GPS (0 vs. 1/2)       and CDDP regimens 
5. Zhou et al., Prospective HCC China 224 GPS (0/1/2) 40 (18) 24 (11) GPS: 99 GPS: 101 GPS: 24 TRACE chemotherapy 
 2015a        (44.2) (45.1) (10.7)  
      mGPS (0/1/2)   mGPS: 115 mGPS: 85 mGPS: 24  
         (51.3) (38.0) (10.7)  
6. Hurwitz et al., Prospective Pancreatic cancer USA 121 mGPS (0/1/2) _ _ 51 (42.2) 34 (28.1) 36 (29.7_ Capecitabine vs 
 2015            Capecitabine and 
             ruxolitinib 
Combined Total     4507    2985 (66.2) 970 (21.5) 552 (12.3)  
Pulmonary cancer              
operable              
1. Pinato et al., Retrospective Lung cancer UK Total:220 GPS (0/1/2) 66 (31) 65 (32) 131 (65.8) 39 (19.6) 29 (14.6) Adjuvant radiotherapy 
 2014    mGPS: 199        and chemotherapy 
2. Miyazaki Retrospective NSCLC Japan 94 GPS (0/1/2) _ _ 65 (67) 25 (25.8) 7 (7.2) Neoadjuvant and 
 et al., 2015            adjuvant therapy not 
             specified 
3. Kawashima Retrospective Lung cancer Japan 1043 GPS (0/1/2) 98 (9.4) 87 (8.3) 897 (86) 107 (10) 39 (4) Neoadjuvant and 
 et al., 2015            adjuvant therapy not 
             specified 
4. Fan et al., Retrospective Non-small cell lung China 1243 GPS (0/1/2) 379 (30.5) 154 (12.4) 813 (65.4) 327 (26.3) 103 (8.3) 55.0% patients received 
 2016  cancer   mGPS (0/1/2)       chemotherapy and 17.7% 
             patients received 
             radiotherapy 
Pulmonary cancer              
Inoperable              
1. Forrest et al., Retrospective NSCLC UK 161 GPS (0/1/2) 132 (82) 22 (22) 27 (16.8) 101 (62.7) 33 (20.5) Chemotherapy mainly 
 2003            cisplatin and radical 
             radio 
2. Leung et al., Retrospective Lung cancer UK 261 mGPS (0/1/2) 149 (57) 41 (16) 59 (22.6) 163 (62.4) 39 (15.0) Chemotherapy (mainly 
 2012            platinum based) and/or 
             radical radiotherapy 
3. Gioulbasanis Retrospective Lung cancer Greece 96 GPS (1&2) _ _ 68 (70.8) 18 (18.8) 10 (10.4) Platinum-based 
 et al., 2012            chemotherapy 
4. Simmons Prospective Lung cancer Greece 390 mGPS (0/1/2) 287 (73.6) _ 103 (26.4) 183 (46.9) 104 (26.7) Best supportive care 
 et al., 2015             
5. Zhou et al., Retrospective Lung cancer China 359 mGPS 1&2 21 (33.7) 20 (5.6) 238 (66.3) 110 (30.6) 11 (3.1) Radiotherapy and 
 2015b            chemotherapy 
             (Irinotecan, Etoposide) 
6. Jiang et al., Prospective Lung cancer China 138 GPS: 1&2 _ _ 95 (68.8) 32 (23.2) 11 (8.0) Cisplatin based 
 2015            chemotherapy 
7. Rinehart Prospective Lung cancer USA 51 GPS (0/1/2) _ _ 9 32 10  Carboplatin and 
 et al., 2013            gemcitabine with or 
             without dexamethasone 
Combined Total     4035    2502 (62.0) 1137 (28.2) 396 (9.8)  
Multiple Cancers              
Operable              
Multiple Cancers              
Inoperable              
1. Chua et al., Prospective Multiple Australia 68 mGPS (1&2) 43 (63.2) 17 (25.0 21 (31) 34 (50) 13 (19) Single unit docetaxel 
 2012            treatment  































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































operable colorectal cancer. These studies included both retrospective (n  
= 26) and prospective studies (n = 3). These included studies carried out in 
the UK (n = 15), Japan (n = 11), China (n = 1), Korea (n = 1) and Australia (n 
= 1). In total 3,356 (38%) of patients were system-atically inflamed (Tables 1 
and 2).  
Eight studies including 1,166 patients were identified in inoperable 
colorectal cancer. These studies included both retrospective (n = 6) and 
prospective studies (n = 2). These included studies carried out in the UK (n = 
2), Japan (n = 2), France (n = 1), Korea (n = 1), Australia (n = 1) and 
Norway/Denmark (n = 1). In total 622 (53%) of patients were systematically 
inflamed (Tables 1 and 3). 
 
4.10. Studies of the systemic inflammatory response in patients with head 
and neck cancer 
 
A single study was identified in patients with operable head and neck 
cancer. This contained 178 patients, was retrospective, carried out in the UK 
and showed that 47 (26%) of patients were systemically in-flamed (Tables 1 
and 2). Three studies including 531 patients were identified in inoperable head 
and neck cancer. These studies included both retrospective (n = 1) and 
prospective studies (n = 1). These in-cluded studies carried out in Taiwan (n = 
2) and China (n = 1). In total 251 (47%) of patients were systematically 
inflamed (Tables 1 and 3). 
 
4.11. Studies of the GPS/ mGPS in patients with Hepato Pancreato Biliary 
Cancer 
 
Sixteen studies including 3,587 patients were identified in operable hepato 
pancreato biliary cancer. These studies included both retro-spective (n = 14) 
and prospective studies (n = 2). These included studies carried out in Japan (n 
= 8), the UK (n = 2), China (n = 4), Italy (n = 1), and Austria (n = 1). In total 
1,001 (28%) of patients were systematically inflamed (Tables 1 and 2). 
 
Seven studies including 920 patients were identified in inoperable hepato 
pancreato biliary cancer. These studies included both retro-spective (n = 5) 
and prospective studies (n = 2). These included stu-dies carried out in Japan 
(n = 3), UK (n = 1), USA (n = 1), China (n =  
1) and Australia (n = 1). In total 333 (36%) of patients were system-atically 
inflamed (Tables 1 and 3). 
 
4.12. Studies of the GPS/ mGPS in patients with Pulmonary Cancer 
 
Four studies including 2,579 patients were identified in operable 
pulmonary cancer. All of these studies were retrospective. These in-cluded 
studies carried out in the Japan (n = 2), UK (n = 1) and China (n = 1). In total 
1,001 (27.9) of patients were systematically inflamed (Tables 1 and 2). 
 
Seven studies including 1,456 patients were identified in inoperable 
pulmonary cancer. These studies included were both retrospective (n =  
4) and prospective studies (n = 3). These included studies carried out in the 
UK (n = 2), China (n = 2), Greece (n = 2) and the USA (n = 1). In total 857 
(59%) of patients were systematically inflamed (Tables 1 and 3). 
 
 
4.13. Studies of the GPS/mGPS in patients with Multiple Cancer Types 
 
No articles were identified in patients with operable multiple types of 
cancer. Seven studies including 4,867 patients were identified in inoperable 
multiple cancer types. These studies included both retro-spective (n = 3) and 
prospective studies (n = 4). These included stu-dies carried out in the UK (n = 
2), Australia (n = 2), USA (n = 1), Japan (n = 1) and Norway (n = 1). In total 
3,556 (73%) of patients were systematically inflamed (Tables 1 and 3). 
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Table 2  
Summary of studies using GPS/mGPS to stratify patients undergoing operative and non-operative treatment for cancer.  
 
 Patients (n) GPS/mGPS 0 GPS/mGPS 1 GPS/mGPS 2 
     
Breast cancer 181 100 (55.2) 61 (33.7) 20 (11.1) 
Bladder cancer 2200 1443 (65.6) 613 (27.9) 144 (6.5) 
Gynaecological cancer 1594 999 (62.7) 394 (24.7) 201 (12.6) 
Prostate cancer 223 158 (70.9) 43 (19.3) 22 (9.9) 
Gastro-oesophageal cancer 9590 6941 (72.4) 1670 (17.4) 979 (10.2) 
Haematological cancer 430 90 (20.9) 165 (38.4) 175 (40.7) 
Renal cancer 2559 1741 (68.0) 529 (20.7) 289 (11.3) 
Colorectal cancer 9998 6020 (60.2) 2503 (25.0) 1475 (14.8) 
Head and Neck cancer 709 411 (58.0) 202 (28.5) 96 (13.5) 
Hepato Pancreato Biliary cancer 4507 2985 (66.2) 970 (21.5) 552 (12.3) 
Pulmonary cancer 4035 2502 (62.0) 1137 (28.2) 396 (9.8) 
Multiple cancer 4867 1311 (26.9) 1179 (24.2) 2377 (48.8) 
      
 
Table 3  
Summary of studies using mGPS to stratify patients undergoing operative and non-
operative treatment for cancer. 
  
 Patients (n) GPS/ GPS/ GPS/mGPS 
  mGPS 0 mGPS 1 2  
       
Breast Cancer       
Operative _ _  _ _  
Non-operative 181 100 (55.2) 61 (33.7) 20 (11.1) 
Bladder cancer       
Operative 2133 1410 596 (27.9) 127 (6.0) 
  (66.1)    
Non-operative 67 33 (49.3) 17 (25.4) 17 (25.4) 
Gynaecological cancer       
Operative 724 538 (74.3) 144 (19.9) 42 (5.8) 
Non-operative 870 461 (53.0) 250 (28.7) 159 (18.3) 
Prostate cancer       
Operative _ _  _ _  
Non-operative 223 158 (70.8) 43 (19.3) 22 (9.9) 
Gastro-oesophageal cancer       
Operative 7693 6076 1068 549 (7.1) 
  (79.0) (13.9)   
Non-operative 1897 865 (45.6) 602 (31.7) 430 (22.7) 
Haematological cancer       
Operative _ _  _ _  
Non-operative 430 90 (20.9) 165 (38.4) 175 (40.7) 
Renal cancer       
Operative 2417 1700 451 (18.7) 266 (11.0) 
  (70.3)    
Non-operative 142 41 (28.9) 78 (54.9) 23 (16.2) 
Colorectal cancer       
Operative 8832 5476 2088 1268 
  (62.0) (23.6) (14.4) 
Non-operative 1166 544 (46.7) 415 (35.6) 207 (17.7) 
Head and Neck cancer       
Operative 178 131 (74) 25 (14) 22 (12) 
Non-operative 531 280 (52.7) 177 (33.3) 74 (14.0) 
Hepato Pancreato Biliary       
cancer       
Operative 3587 2586 673 (18.8) 328 (9.1) 
  (72.1)    
Non-operative 920 399 (43.4) 297 (32.3) 224 (24.3) 
Pulmonary cancer       
Operative 2579 1903 498 (19.3) 178 (6.9) 
  (73.8)    
Non-operative 1456 599 (41.1) 639 (43.9) 218 (15.0) 
Multiple cancers       
Operative _ _  _ _  
Non-operative 4867 1311 1179 2377 
  (26.9) (24.2) (48.8) 
Total Operative 28,143      
Total Non-operative 12,750      
Combined Total 40,893      
       
 
4.14. Combined Inoperable and Operable Studies 
 
Inoperable and operable cancer studies are summarised in Tables 2 and 3. 
The percentage of patients with operable cancer (n > 28,000) 
 
who were systemically inflamed varied from 21% to 38% (gastro-esophageal 
and colorectal cancer respectively Table 3). The most commonly studied 
cancer was colorectal cancer (n > 8,500 patients) and 38% were systemically 
inflamed (Table 3). The percentage of pa-tients with inoperable cancer (n > 
12,000) who were systemically in-flamed varied from 29% to 79% (prostate 
and haematological cancers, Table 3). Furthermore, a commonly studied 
cancer was colorectal cancer (n > 1,100 patients) and 53% were systemically 
inflamed (Table 3). Overall, the percentage of patients (n > 40,000) who were 
systemically inflamed varied from 28% to 63% according to tumour type 
(gastroesophageal and multiple cancers respectively). The most commonly 
studied cancer was colorectal cancer (n∼10,000 patients) and 40% were 





In the present narrative review of the prevalence of the systemic 
inflammatory response (as evidenced by GPS/mGPS) in more than 40,000 
patients with cancer it was clear that the elevation of the GPS/ mGPS was 
common and the prevalence was greater in advanced cancer compared with 
operable cancer. In particular, of the patients with op-erable cancer, no 
specific tumour type had more than 50% of patients with an elevated systemic 
inflammatory response as measured by the GPS/mGPS. In contrast, of the 
patients with inoperable cancers, gastro-oesophageal cancer, colorectal 
cancer, hepato pancreato biliary cancer, pulmonary cancer and multiple 
cancers all had more than 50% of pa-tients with an elevated systemic 
inflammatory response as measured by the GPS/mGPS. Therefore, it is clear 
that the presence of a systemic inflammatory response is a common 
prognostic feature of established cancer, especially advanced cancer. 
 
The results of the present review are consistent with the report of Proctor 
and colleagues who first studied the prevalence of the mGPS before and after 
diagnosis in an unselected cohort of patients with cancer and reported that 
“the proportions of mGPS 1 and 2 were greater following a diagnosis of 
cancer (Proctor et al., 2010).” Taken together these results would indicate that 
the systemic inflammatory response is present at the earliest stages of cancer 
and increases as the cancer progresses. Given the independent prognostic 
value of the mGPS this may suggest that the systemic inflammatory response 
reflects or pro-motes tumour progression. Irrespective, these results have 
implications for the future stratification and treatment of both operable and in-
operable disease in patients with cancer. 
 
The implications for patient stratification are clear and there is now 
evidence of the GPS/mGPS being used in the randomised clinical trial setting 
(Dolan et al., 2018a). However, the importance of the systemic inflammatory 
response in the development of cachexia (Cederholm et al., 2017, Cederholm 
et al., 2019) and in particular the loss of lean tissue (Abbass et al., 2019) is of 
considerable importance since it highlights those patients likely to develop 
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inoperable). The implications for treatment to mitigate the effects of the 
systemic inflammatory response are less clear in patients with breast cancer 
and operable cancer. In contrast, in lung cancer and in advanced inoperable 
cancer there are clear implications for the use of the sys-temic inflammatory 
response as a therapeutic target (Diakos et al., 2014). 
 
In summary, the systemic inflammatory response, as evidenced by the 
GPS/mGPS, was common in both primary operable and advanced inoperable 
cancers particularly in patients with cancers of the lungs and gastrointestinal 
tract. Therefore, the systemic inflammation “iceberg” is in plain sight and 
should be factored into future treatment plans of patients with cancer. 
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